Kettner W, Banditt P, Walther H
Dtsch Z Verdau Stoffwechselkr. 1983;43(6):255-66.
As it was demonstrated in a study, antipyrin halftime and clearance totalis are prolonged resp. reduced in patients with circulatory liver damage due to cardiac failure in myocardial infraction (group H) and in patients with chronic congested liver due to diseases of the heart valves (group V). group H: t50,2 +/- 11,7 h, Cltot 27 +/- 13,3 ml. min-1; group V: t50 19,3 +/- 6,3 h, Cltot 21,9 +/- 8,6 ml. min-1. Those patients with acute myocardial infarction and normal liver condition had a prolonged half-time as well though the clearance was decreased just insignificantly (t50 12 +/- 4,9 h, Cltot 42,6 +/- 15,8 ml. min-1). In the three groups we obtained the expected biochemical results. There was only a slight correlation of both the antipyrin half-time and the clearance totalis to biochemical parameters, Conclusions: In chronic inflammatory liver diseases and other forms of hepatic malfunctions as well as in circulatory liver damages the antipyrin half-time is influenced. Because of this reason, reduction of metabolic capacity should be expected. It is referred to necessary adaptation of the drug doses if capacity limiting medicaments are administered to patients with circulatory liver damage.
一项研究表明,在因心肌梗死导致心力衰竭的循环性肝损伤患者(H组)和因心脏瓣膜疾病导致慢性充血性肝的患者(V组)中,安替比林半衰期和总清除率分别延长和降低。H组:t50,2±11.7小时,Cltot 27±13.3毫升·分钟-1;V组:t50 19.3±6.3小时,Cltot 21.9±8.6毫升·分钟-1。急性心肌梗死且肝脏状况正常的患者半衰期也延长,不过清除率仅略有下降(t50 12±4.9小时,Cltot 42.6±15.8毫升·分钟-1)。在这三组中我们获得了预期的生化结果。安替比林半衰期和总清除率与生化参数之间仅有轻微相关性。结论:在慢性炎症性肝病和其他形式的肝功能障碍以及循环性肝损伤中,安替比林半衰期会受到影响。因此,预计代谢能力会降低。如果对循环性肝损伤患者使用容量限制性药物,有必要调整药物剂量。